면역세포와 암세포의 상호작용

키워드

참고문헌 (42)

1. Burnet M, "Cancer; a biological approach. I. The processes of control", Br Med J, 1(5022), pp.779~786 (1957)
2. Dunn GP, "Cancer immunoediting: from immunosurveillance to tumor escape", Nat Immunol, 3(11), pp.991~998 (2002)
3. Mantovani A, "Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes", Trends Immunol, 23(11), pp.549~555 (2002)
4. Mantovani A, "Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation", Hum Immunol, 70(5), pp.325~330 (2009)
5. Mantovani A, "Macrophages, innate immunity and cancer: balance, tolerance, and diversity", Curr Opin Immunol, 22(2), pp.231~237 (2010)
6. Steidl C, "Tumor-associated macrophages and survival in classic Hodgkin's lymphoma", N Engl J Med, 362(10), pp.875~885 (2010)
7. Youn JI, "Subsets of myeloid-derived suppressor cells in tumor-bearing mice", J Immunol, 181(8), pp.5791~5802 (2008)
8. Hestdal K, "Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells", J Immunol, 147(1), pp.22~28 (1991)
9. Almand B, "Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer", J Immunol, 166(1), pp.678~689 (2001)
10. Ochoa AC, "Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma", Clin Cancer Res, 13(2 Pt 2), pp.721s~726s (2007)
11. Schmielau J, "Activated granulocytes and granulocytederived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients", Cancer Res, 61(12), pp.4756~4760 (2001)
12. Gabrilovich DI, "Myeloid-derived suppressor cells as regulators of the immune system", Nat Rev Immunol, 9(3), pp.162~174 (2009)
13. Kusmartsev S, "All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination", Cancer Res, 63(15), pp.4441~4449 (2003)
14. Mirza N, "All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients", Cancer Res, 66(18), pp.9299~9307 (2006)
15. Lathers DM, "Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3", Cancer Immunol Immunother, 53(5), pp.422~430 (2004)
16. Caillou B, "Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma", PLoS One, 6(7), pp.e22567~ (2011)
17. Ryder M, "Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer", Endocr Relat Cancer, 15(4), pp.1069~1074 (2008)
18. Wei Q, "Density of Tumor Associated Macrophage Correlates with Lymph Node Metastasis in Papillary Thyroid Carcinoma", Thyroid (2012)
19. Allavena P, "Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production", Cancer Res, 65(7), pp.2964~2971 (2005)
20. Germano G, "Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells", Cancer Res, 70(6), pp.2235~2244 (2010)
21. Muta M, "Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation", Clin Cancer Res, 12(1), pp.264~272 (2006)
22. Bundred NJ, "Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial", Clin Cancer Res, 16(5), pp.1605~1612 (2010)
23. Antonarakis ES, "Phase II, randomized, placebocontrolled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers", J Clin Oncol, 27(30), pp.4986~4993 (2009)
24. Gazzaniga S, "Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft", J Invest Dermatol, 127(8), pp.2031~2041 (2007)
25. Miselis NR, "Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma", Mol Cancer Ther, 7(4), pp.788~799 (2008)
26. Meng Y, "Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy", Cancer Res, 70(4), pp.1534~1543 (2010)
27. Tsagozis P, "Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages", Cancer Immunol Immunother, 57(10), pp.1451~1459 (2008)
28. Watkins SK, "Rapid release of cytoplasmic IL-15 from tumorassociated macrophages is an initial and critical event in IL-12- initiated tumor regression", Eur J Immunol, 39(8), pp.2126~2135 (2009)
29. Watkins SK, "IL-12 rapidly alters the functional profile of tumor-associated and tumorinfiltrating macrophages in vitro and in vivo", J Immunol, 178(3), pp.1357~1362 (2007)
30. Hagemann T, ""Re-educating" tumor-associated macrophages by targeting NF-kappaB", J Exp Med, 205(6), pp.1261~1268 (2008)
31. Rolny C, "HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF", Cancer Cell, 19(1), pp.31~44 (2011)
32. Kluza E, "Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity", J Control Release, 151(1), pp.10~17 (2011)
33. Canioni D, "High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial", J Clin Oncol, 26(3), pp.440~446 (2008)
34. Pan PY, "Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function", Blood, 111(1), pp.219~228 (2008)
35. Fricke I, "Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses", Clin Cancer Res, 13(16), pp.4840~4848 (2007)
36. Kusmartsev S, "Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma", J Immunol, 181(1), pp.346~353 (2008)
37. Sinha P, "Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells", Cancer Res, 67(9), pp.4507~4513 (2007)
38. Serafini P, "Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function", J Exp Med, 203(12), pp.2691~2702 (2006)
39. Melani C, "Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma", Cancer Res, 67(23), pp.11438~11446 (2007)
40. Suzuki E, "Gemcitabine selectively eliminates splenic Gr-1+", CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, 2005, pp.11(18), 6713~6721
41. Ko HJ, "A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model", Cancer Res, 67(15), pp.7477~7486 (2007)
42. De Santo C, "Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination", Proc Natl Acad Sci U S A, 102(11), pp.4185~4190 (2005)